Investors focused on the Medical space have likely heard of Lineage Cell Therapeutics (LCTX - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of LCTX and the rest of the Medical group's stocks.
Lineage Cell Therapeutics is a member of the Medical sector. This group includes 892 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. LCTX is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for LCTX's full-year earnings has moved 6.85% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that LCTX has returned about 7.30% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 3.46% on average. This shows that Lineage Cell Therapeutics is outperforming its peers so far this year.
Looking more specifically, LCTX belongs to the Medical - Biomedical and Genetics industry, which includes 382 individual stocks and currently sits at #11 in the Zacks Industry Rank. This group has gained an average of 3.96% so far this year, so LCTX is performing better in this area.
Investors in the Medical sector will want to keep a close eye on LCTX as it attempts to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of Lineage Cell Therapeutics (LCTX - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of LCTX and the rest of the Medical group's stocks.
Lineage Cell Therapeutics is a member of the Medical sector. This group includes 892 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. LCTX is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for LCTX's full-year earnings has moved 6.85% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that LCTX has returned about 7.30% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 3.46% on average. This shows that Lineage Cell Therapeutics is outperforming its peers so far this year.
Looking more specifically, LCTX belongs to the Medical - Biomedical and Genetics industry, which includes 382 individual stocks and currently sits at #11 in the Zacks Industry Rank. This group has gained an average of 3.96% so far this year, so LCTX is performing better in this area.
Investors in the Medical sector will want to keep a close eye on LCTX as it attempts to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on LCTX - FREE